Nicox: Participation in financial and scientific conferences in the third quarter of 2022








Press release
Nicox: Participation in financial and scientific conferences in the third quarter of 2022
August 3, 2022 – broadcast at 7:30 am

Sophia-Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX, PEA-PME eligible), an international company specializing in ophthalmology, today announces that members of the management team will participate in the financial and scientific conferences listed below, in Europe and the United States , In the coming months :

Confeences financial

Andreas Segerros, Managing Director of Nicox, will present at these conferences. Members of the management team will participate in individual meetings with investors.

Confeences scientists

Doug Hubatsch, Chief Scientific Officer of Nicox, will make a presentation. Members of the management team, including Andreas Segerros, Managing Director, will participate in individual meetings.

About Nicox

Nicox SA is an international company specializing in ophthalmology developing innovative solutions aimed at maintaining vision and improving eye health. The Company’s main program in clinical development is NCX 470, a new nitric oxide-donating prostaglandin analogue, for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. Nicox is also developing NCX 4251, a patented formulation of fluticasone, for dry eye. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb and ZERVIATE® in allergic conjunctivitis. ZERVIATE is licensed in several territories, including Eyevance Pharmaceuticals, LLC, for the United States and Ocumension Therapeutics for the Chinese market and the majority of Southeast Asian countries.

Nicox, whose head office is in Sophia Antipolis (France), is listed on Euronext Paris (Compartment C: Mid Caps; Ticker: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indices.

For more information on Nicox, its products or its portfolio: www.nicox.com

Analyst coverage
Bryan, Garnier & Co Dylan Van Haaften Paris, France
Edison Investment Research Pooya Hemami London, United Kingdom
HC Wainwright & Co Yi Chen New York, USA
Kepler Cheuvreux Arsene Guekam France, United States
The positions expressed by analysts in their notes on Nicox are their own and do not reflect those of the Company. In addition, the information contained in their reports may not be correct or up to date. Nicox disclaims any obligation to correct or update information contained in analyst reports.
contacts

Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
[email protected]

Investor and Media Relations
USA & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
[email protected]

Forward-looking statements
The information contained in this document may be modified without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on the current expectations and beliefs of Nicox SA’s management team and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox SA and its affiliates, directors, officers, employees, advisors or agents do not undertake and are not obligated to update any forward-looking statement or to revise any forward-looking statement.

The risk factors likely to have a significant impact on Nicox SA’s business are set out in Chapter 3 of the 2021 Universal Registration Document, Annual Report and Management Report which was filed with the AMF on April 29, 2022. and which is available on the Nicox website (www.nicox.com).

Nicox S.A.
Longship 2
Building D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99
  • FR _ Q3 2022 conferences PR_20220803_F

All the news on NICOX SA.

Analyst recommendations for NICOX SA.

2022 turnover 2.95M
3.01M
2022 net result -20.4M
-20.8M
trso. net 2022 2.49M
2.54M
PER 2022-3.89x
2022 return
Capitalization 78.9M
80.5M
VE / CA 202225.9x
VE / CA 202310.6x
Number of employees33
Floating89.1%


Hard :

Period:




Nicox SA.  : Chart technical analysis Nicox SA.  |  Market area

Trends technical analysis NICOX SA.

Short termMiddle termLong term
TrendsNeutralbearishbearish

Evolution of the Income Statement

Sale

Purchase

Average recommendationACCUMULATE
Number of Analysts2
Last Closing Price€1.83
Average price target€12.00
Deviation / Average Target557%

Officers and Directors




Source link -88